Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomesdoi:10.1007/s40291-024-00699-wWhilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In...
177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherap...
Whilst prostate cancer is the fourth most common cancer globally, effective therapies for patients with advanced disease are lacking. In recent years, interest in using theranostic agents to treat castrate-resistant prostate cancer (CRPC) and metastatic prostate cancer has emerged. Lu-TLX591 monoclonal...
every 6 weeks for up to a total of 6 doses plus bsoc or bsoc alone. bsoc administered at the investigator’s discretion included ketoconazole; radiation therapy to localized prostate cancer targets; bone-targeted agents; androgen-reducing agents; ar pathway inhibitors. patients continued ...
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the...
If you have advanced prostate cancer, you know every day matters. PLUVICTO could give you more time for what's important to you and your loved ones. That's a victory. See How PLUVICTO May Help After hormone therapy and chemotherapy, ask about PLUVICTO. ...
Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer. Cancers. 2021;13:2011. Article CAS PubMed PubMed Central Google Scholar Bernhardt P, Benjegård SA, Kölby L, et al. Dosimetric comparison of radionuclides for therapy of ...
Due to its overexpression on the surface of prostate cancer cells, PMSA remains a useful protein target for targeted diagnostic processes and radionuclide therapy in prostate cancer. Lutetium Lu 177 vipivotide tetraxetan consists of lutetium Lu-177, a radionuclide and an active moiety of the drug,...
FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year survival rate of less than 30%3; mCRPC patients who progress on multiple lines of therapy have limited trea...
Radioligand therapy (RLT) using PSMA-targeting ligands is an emerging therapeutic option in men with metastatic castration-resistant prostate cancer (mCRPC). However, more than half of mCRPC patients treated with PSMA RLT eventually fail therapy [1, 2]. Reasons for disease progression or patient ...